Cardiol Therapeutics (CRDL) Shares Outstanding (Weighted Average) (2020 - 2026)

Cardiol Therapeutics has reported Shares Outstanding (Weighted Average) for 7 years, with the latest figure at $155.2 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Weighted Average) rose 222661804.4% year-over-year to $155.2 million; the trailing twelve-month figure through Mar 2026 stood at $155.2 million (up 222661804.4% YoY), and the FY2025 full-year result was $144.8 million, up 182.55% from the prior year.
• Shares Outstanding (Weighted Average) for Q1 2026 stood at $155.2 million, up from $144.8 million in the prior quarter.
• The five-year high for Shares Outstanding (Weighted Average) was $155.2 million in Q1 2026, with the low at $69.69 in Q1 2025.
• Historically, Shares Outstanding (Weighted Average) has averaged $37.5 million across 5 years, with a median of $238.7 in 2023.
• Annual changes were most pronounced in 2022 — Shares Outstanding (Weighted Average) slumped 100.0% — and 2026, when it surged 222661804.4%.
• Cardiol Therapeutics' Shares Outstanding (Weighted Average) stood at $108.7 million in 2022, then plunged by 55.84% to $48.0 million in 2023, then climbed by 6.72% to $51.2 million in 2024, then jumped by 182.55% to $144.8 million in 2025, then gained by 7.2% to $155.2 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $155.2 million (Q1 2026), $144.8 million (Q4 2025), and $232.52 (Q3 2025), per Business Quant data.